The prevalence of pre-thyroidectomy thyroid function test abnormalities among patients with differentiated thyroid carcinoma: A descriptive study

Document Type : Original Article


Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran



Introduction: The present study aims to assess pre-thyroidectomy thyroid hormone disturbances among patients suffering from differentiated thyroid carcinoma (DTC).
Methods: This retrospective study was performed from September 2020 to March 2021. We analyzed the hospital files of 710 patients with DTC who underwent thyroidectomy and referred to nuclear medicine department from April 2013 to September 2019. Demographics, TNM stage, pre-surgery thyroid function tests, time-interval to achieve a complete response, recurrence rate, one-year response, final response, and the need for alternative treatment modalities were extracted. Then, we analyzed the potential association of pre-surgery TSH levels with the initial disease stage and treatment response. Chi-Square, Analysis-of-variance, and Kruskal-Wallis tests were used where appropriate.
Results: The mean age of participants was 40.39 ± 13.85 years. History of Hashimoto's disease was detected in 130 (18.3%) patients. Multi-focal DTC was found in 221 (31.2%) patients. Lymph node involvement was significantly higher among men (p = 0.001). Men also had significantly higher thyroglobulin levels (p = 0.025). No statistically significant association was found between pre-surgery thyroid function status and TNM stage or multifocality of the malignancy. Baseline thyroid function tests also did not show a statistically significant relationship with thyroglobulin, anti-thyroglobulin antibody, time to first excellent response, and follow-up duration.
Conclusion: Baseline thyroid function status may not change the outcome of DTC. It could also be plausible that thyroid dysfunction before surgery would not increase invasiveness nor impact the treatment-response of the tumor compared to euthyroid patients.


Main Subjects

  1. Cancer Stat Facts: Thyroid Cancer. National Cancer Institute [cited 2022 Apr 20]. Available from:
  2. Schmidbauer B, Menhart K, Hellwig D, Grosse J. Differentiated thyroid cancer—treatment: state of the art. Int J Mol Sci. 2017 Jun;18(6):1292.
  3. Barrows CE, Belle JM, Fleishman A, Lubitz CC, James BC. Financial burden of thyroid cancer in the United States: An estimate of economic and psychological hardship among thyroid cancer survivors. Surgery. 2020 Feb;167(2):378-84.
  4. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014 Jun;74(11):2913-21.
  5. Bibbins-Domingo K, Grossman DC, Curry SJ, Barry MJ, Davidson KW, Doubeni CA, Epling Jr JW, Kemper AR, Krist AH, Kurth AE, Landefeld CS, Mangione CM, Phipps MG, Silverstein M, Simon MA, Siu AL, Tseng CW. Screening for thyroid cancer: US Preventive Services Task Force recommendation statement. J Am Med Assoc. 2017 May;317(18):1882-7.
  6. Davies L, Morris LG. The USPSTF recommendation on thyroid cancer screening: don't "check your neck". JAMA Otolaryngol Head Neck Surg. 2017 Aug;143(8):755-6.
  7. Staniforth JU, Erdirimanne S, Eslick GD. Thyroid carcinoma in Graves' disease: a meta-analysis. Int J Surg. 2016 Mar;27:118-25.
  8. Ömür Ö, Yazc B, Akgün A, Özcan Z, Akyldz M, Argon M, Ozklç H. Concomitant hyperthyroidism in patients with thyroid carcinoma and the effects of iodine supplementation in an iodine-deficient area. Clin Nucl Med. 2008 Nov;33(11):769-72.
  9. Premoli P, Tanda M, Piantanida E, Veronesi G, Gallo D, Masiello E, Rosetti S, Cusini C, Boi F, Bulla J, Rodia R, Mariotti S, Capelli V, Rotondi M, Magri F, Chiovato L, Rocchi R, Campopiano MC, Elisei R, Vitti P, Barbato F, Pilli T, Castagna MG, Pacini F, Bartalena L. Features and outcome of differentiated thyroid carcinoma associated with Graves' disease: results of a large, retrospective, multicenter study. J Endocrinol Invest. 2020 Jan;43(1):109-16.
  10. MacFarland SP, Bauer AJ, Adzick NS, Surrey LF, Noyes J, Kazahaya K, Mostoufi-Moab S. Disease burden and outcome in children and young adults with concurrent graves disease and differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2018 Aug;103(8):2918-25.
  11. Zhang X, Zhang X, Chang Z, Wu C, Guo H. Correlation analyses of thyroid-stimulating hormone and thyroid autoantibodies with differentiated thyroid cancer. J BUON. 2018 Sep;23(5):1467-71.
  12. Haymart MR, Repplinger DJ, Leverson GE, Elson DF, Sippel RS, Jaume JC, Chen H. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab. 2008 Mar;93(3):809-14.
  13. Morand G, da Silva S, Mlynarek A, Black M, Payne R, Hier M. Clinicopathological relevance of antithyroglobulin antibodies in low‐risk papillary thyroid cancer. Clin Otolaryngol. 2017 Dec;42(6):1130-4.
  14. Molnár C, Molnár S, Bedekovics J, Mokánszki A, Győry F, Nagy E, Méhes G. Thyroid carcinoma coexisting with Hashimoto's thyreoiditis: clinicopathological and molecular characteristics clue up pathogenesis. Pathol Oncol Res. 2019 Jul;25(3):1191-7.
  15. Ma H, Li L, Li K, Wang T, Zhang Y, Zhang C, Xu Y, Xu X, Yu J, Wang H, Xiang B, Zhang R, Wang W. Hashimoto's thyroiditis, nodular goiter or follicular adenoma combined with papillary thyroid carcinoma play protective role in patients. Neoplasma. 2018 Mar;65(3):436-40.